Elutia, Inc. is a biotechnology company, which engages in the provision of biologic products to improve compatibility between medical devices and the patients who need them. The company is headquartered in Silver Spring, Maryland and currently employs 51 full-time employees. The company went IPO on 2020-10-08. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. The company is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
Follow-Up Questions
Qui est le CEO de Elutia Inc ?
Dr. C. Randal Mills est le President de Elutia Inc, il a rejoint l'entreprise depuis 2015.
Quelle est la performance du prix de l'action ELUT ?
Le prix actuel de ELUT est de $0.8874, il a decreased de 0.37% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Elutia Inc ?
Elutia Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Elutia Inc ?
La capitalisation boursière actuelle de Elutia Inc est de $37.6M
Est-ce que Elutia Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 4 analystes ont établi des notations d'analystes pour Elutia Inc, y compris 2 achat fort, 5 achat, 1 maintien, 0 vente et 2 vente forte
